DM3 acts as an effective ADC cytotoxin payload disrupting DNA replication in tumor cells. Incorporated in antibody-drug conjugates, it boosts selective cancer cell killing with enhanced therapeutic performance.
Structure of 796073-54-6
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
5 mg | $729 | In stock | |
25 mg | $1573 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
DM3 is a potent semi-synthetic derivative of Maytansine and a widely utilized ADC cytotoxin in the development of antibody-drug conjugates. As an ADC payload, DM3 disrupts microtubule polymerization by binding to tubulin, leading to mitotic arrest and apoptosis in rapidly dividing tumor cells. Its structural modifications compared to native Maytansine enhance conjugation efficiency and stability, making DM3 a versatile option for targeted cancer therapy applications.
Within antibody-drug conjugates, DM3 is typically linked to monoclonal antibodies using cleavable or non-cleavable linker strategies, ensuring selective payload release inside tumor cells. The ADC remains stable in systemic circulation, reducing off-target toxicity, while intracellular enzymatic processing liberates DM3 to exert its cytotoxic effects. This mechanism provides high tumor specificity, potent antitumor activity at low drug-to-antibody ratios (DARs), and improved therapeutic index, which are essential for precision oncology applications.
Applications of DM3 include its use in preclinical and clinical ADC candidates targeting hematologic malignancies and solid tumors, such as breast cancer, ovarian cancer, and lymphoma. Its chemical compatibility with diverse linker technologies allows researchers to optimize conjugation efficiency, stability, and intracellular payload release. DM3’s potent cytotoxicity and reliable pharmacokinetics make it a valuable ADC payload for developing next-generation antibody-drug conjugates with enhanced tumor selectivity and antitumor efficacy.
What is DM3?
DM3 is a synthetic cytotoxic molecule derived from the maytansinoid family, utilized as a payload in ADCs. It inhibits microtubule assembly, disrupting mitosis and inducing apoptosis, suitable for targeted antibody conjugation.
2/11/2020
We are interested in how DM3 is applied in ADCs.
DM3 is linked to monoclonal antibodies to achieve selective cytotoxicity toward antigen-expressing cells. This targeted delivery minimizes off-target toxicity and enhances ADC therapeutic efficacy.
27/9/2019
Could you kindly inform us which linkers are effective with DM3?
DM3 can be conjugated using cleavable linkers for intracellular release and non-cleavable linkers for improved circulation stability. The choice of linker affects payload release kinetics and pharmacodynamic profile.
1/1/2019
May I ask what laboratory safety measures are recommended for DM3?
Handling DM3 requires PPE, proper containment, and adherence to institutional and regulatory safety guidelines due to its potent cytotoxicity. Proper waste disposal and safe handling during conjugation are essential.
12/8/2022
Dear BOC Sciences, what research benefits do DM3 ADCs provide?
DM3 ADCs deliver microtubule-targeting cytotoxicity selectively to target cells, enabling precise preclinical studies on antibody specificity, pharmacokinetics, and payload efficacy, supporting the development of safer oncology therapies.
2/7/2019
— Dr. Richard Evans, Senior Scientist (USA)
DM3 showed exceptional purity and stability. Shipment was timely and documentation thorough.
1/1/2019
— Prof. Emily Johnson, Chemical Biology Researcher (Canada)
We relied on BOC Sciences for DM3, and the compound delivered reliable cytotoxicity profiles in our assays. Their responsive support team made the process seamless.
2/7/2019
— Dr. Stefan Weber, Medicinal Chemist (Germany)
Technical support answered all questions and provided full QC reports for DM3.
12/8/2022
— Dr. David Wilson, Biotech Research Scientist (Canada)
The DM3 supplied by BOC Sciences was easy to handle and performed consistently during cytotoxicity assays. Their technical support also provided helpful insights on formulation.
2/11/2020
— Dr. Thomas Wright, Lead Scientist (USA)
High-purity DM3 compound and responsive service. Met all project needs.
— Prof. Anna Müller, Medicinal Chemistry Professor (Germany)
BOC Sciences supplied DM3 with excellent documentation, including HPLC and NMR profiles. This transparency helped us accelerate approval from our internal quality control team.
27/9/2019
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.